Deutsche Bank’s Elicio Therapeutics ELTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20K Sell
11,016
-1,636
-13% -$4.54K ﹤0.01% 3552
2026
Q2
$49.5K Buy
+12,652
New +$127K ﹤0.01% 3568
2022
Q2
– Sell
-1,349
Closed -$29K – 4175
2022
Q1
$29K Sell
1,349
-140
-9% -$3.16K ﹤0.01% 3983
2021
Q4
$43K Buy
1,489
+75
+5% +$3.79K ﹤0.01% 3998
2021
Q3
$138K Buy
1,414
+1,059
+298% +$114K ﹤0.01% 3750
2021
Q2
$46K Sell
355
-11
-3% -$1.59K ﹤0.01% 4323
2021
Q1
$66K Buy
+366
New +$70.6K ﹤0.01% 4163

Other funds holding ELTX

Deutsche Bank's ELTX Position: Q3 2026 in Review

Deutsche Bank reduced its Elicio Therapeutics (ELTX) stake by 13% in Q3 2026, selling an estimated $4.54K and leaving 11,016 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #3552.

Deutsche Bank first reported a position in ELTX in Q1 2021 and has held it in 7 quarters since. The position peaked at $138K in Q3 2021. 79 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Deutsche Bank held 11,016 shares of Elicio Therapeutics worth $20K as of Q3 2026.
  • Deutsche Bank sold 1,636 Elicio Therapeutics shares in Q3 2026, an estimated $4.54K.
  • Elicio Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #3552 holding.
  • Deutsche Bank first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 7 quarters since.
  • Deutsche Bank's Elicio Therapeutics position peaked at $138K in Q3 2021.
  • 79 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.